News in brief: Psoriasis and eczema biologics win PBAC approval; Melanoma expert takes on editor role; Australian dermatologists use erlotinib for PKK

Psoriasis and eczema biologics win PBAC approval The Pharmaceutical Benefits Advisory Committee (PBAC) has made a positive recommendation for PBS listing of secukinumab (Cosentyx) for the treatment of paediatric patients with severe chronic plaque psoriasis. At its November 2021 meeting the PBAC said it was satisfied that secukinumab was non-inferior to ustekinumab in this indication ...

Already a member?

Login to keep reading.

© 2022 the limbic